| High and Interrelated Rates of PD-L1+CD14+ Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from … AM Heeren, BD Koster, S Samuels, DM Ferns, D Chondronasiou, ... Cancer immunology research 3 (1), 48-58, 2015 | 134 | 2015 |
| Unlocking the therapeutic potential of primary tumor-draining lymph nodes J Rotman, BD Koster, ES Jordanova, AM Heeren, TD de Gruijl Cancer Immunology, Immunotherapy 68, 1681-1688, 2019 | 68 | 2019 |
| Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I–II melanoma: data from two randomized phase II trials BD Koster, MFCM Van Den Hout, BJR Sluijter, BG Molenkamp, ... Clinical Cancer Research 23 (19), 5679-5686, 2017 | 68 | 2017 |
| Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141+ Dendritic Cells … BJR Sluijter, MFCM van den Hout, BD Koster, PAM van Leeuwen, ... Cancer immunology research 3 (5), 495-505, 2015 | 65 | 2015 |
| Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence MFCM Van Den Hout, BD Koster, BJR Sluijter, BG Molenkamp, ... Cancer immunology research 5 (11), 969-977, 2017 | 41 | 2017 |
| Recent developments and future challenges in immune checkpoint inhibitory cancer treatment BD Koster, TD de Gruijl, AJM van den Eertwegh Current opinion in oncology 27 (6), 482-488, 2015 | 30 | 2015 |
| Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation KM van Pul, JCL Notohardjo, MF Fransen, BD Koster, AGM Stam, ... Science immunology 7 (73), eabn8097, 2022 | 26 | 2022 |
| Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell … BD Koster, SJAM Santegoets, J Harting, A Baars, SM van Ham, ... Cancer Immunology, Immunotherapy 68, 1025-1035, 2019 | 15 | 2019 |
| T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A+ CD141+ cDC1 and CD14+ antigen-presenting cell recruitment BD Koster, ML González, MFCM van den Hout, AW Turksma, BJR Sluijter, ... Journal for immunotherapy of cancer 9 (3), 2021 | 10 | 2021 |
| Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence. Cancer Immunol Res.(2017) 5: 969–77. doi: 10.1158 … M van den Hout, BD Koster, BJR Sluijter, BG Molenkamp, R van de Ven, ... CIR-17-0110, 0 | 10 | |
| In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma BD Koster, TD de Jong, MFCM van den Hout, BJR Sluijter, RJ Vuylsteke, ... Oncoimmunology 9 (1), 1708066, 2020 | 9 | 2020 |
| Response: breslow thickness and excision interval affect the activation state of Langerhans cells in melanoma sentinel lymph nodes MFCM van den Hout, BD Koster, BJR Sluijter, PAM van Leeuwen, ... Blood, The Journal of the American Society of Hematology 119 (20), 4809-4810, 2012 | 5 | 2012 |
| Pre-operative intradermal administration of CpG-B±GM-CSF in stage I-III melanoma patients arms the sentinel lymph node: evidence for reduced tumor spread MF van den Hout, BD Koster, RJ Scheper, R van de Ven, BJ Sluijter, ... Journal for ImmunoTherapy of Cancer 1, 1-1, 2013 | 2 | 2013 |
| LBA43 Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: Interim efficacy and safety results of the randomized phase II … JCL Notohardjo, S Veenstra, BD Koster, V Kandiah, S Van der Velde, ... Annals of Oncology 33, S1410, 2022 | 1 | 2022 |
| Application of TLR agonists in cancer immunotherapy: from late to early, from systemic to local BD Koster | | 2020 |
| Local adjuvant treatment of clinical stage I-II melanoma with low dose CpG-B and/or GM-CSF: Long-term follow-up of three randomized controlled phase II trials BD Koster, MF Hout, BJ Sluijter, BG Molenkamp, RJ Vuylsteke, A Baars, ... Cancer Research 77 (13_Supplement), 4692-4692, 2017 | | 2017 |
| Local administration of CpG-B increases recurrence-free survival in early-stage melanoma patients: Long-term follow-up of two randomized clinical trials evaluating adjuvant … TD de Gruijl, BD Koster, MFCM van den Hout, BJR Sluijter, ... CANCER IMMUNOLOGY RESEARCH 4 (1), 2016 | | 2016 |
| Abstract A050: Local administration of CpG-B increases recurrence-free survival in early-stage melanoma patients: Long-term follow-up of two randomized clinical trials … TD Gruijl, BD Koster, MFCM Hout, BJR Sluijter, BG Molenkamp, ... Cancer Immunology Research 4 (1_Supplement), A050-A050, 2016 | | 2016 |
| Single low-dose administration of anti-CTLA-4/tremelimumab at the tumor excision site boosts systemic antitumor immunity in early-stage melanoma patients: Results from a Phase … AGM Stam, KM van Pul, BD Koster, D Chondronasiou, SM Lougheed, ... CANCER IMMUNOLOGY RESEARCH 4 (1), 2016 | | 2016 |
| Abstract B138: Single low-dose administration of anti-CTLA-4/tremelimumab at the tumor excision site boosts systemic antitumor immunity in early-stage melanoma patients … AGM Stam, KM Pul, BD Koster, D Chondronasiou, SM Lougheed, MP Tol, ... Cancer Immunology Research 4 (1_Supplement), B138-B138, 2016 | | 2016 |
